NDA 220200 · Avyxa Holdings
Avopef
Etoposide · Intravenous · Topoisomerase Inhibitor
Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 13, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,914
435 Phase 3, 235 recruiting
FAERS reports
73,447
71,494 serious, 17,829 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE MYELOSUPPRESSION AVOPEF can cause severe myelosuppression resulting in infection or bleeding [see Warnings and Precautions (5.1) ] . Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm 3 or platelets less than 50,000 cells/mm 3 [see Warnings and Precautions (5.1) ] . Monitor complete blood cell counts, prior to the administration of AVOPEF and before each subsequent cycle, and at appropriate intervals during and after therapy [see Warnings and Precautions (5.1) ] . WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning . AVOPEF can cause severe myelosuppression resulting in infection or bleeding. ( 5.1 ) Do not administer AVOPEF to patients with absolute neutrophil counts of less than 500 cells/mm 3 or platelets less than 50,000 cells/mm 3 . ( 5.1 ) Monitor complete blood cell counts, prior...
What it is approved for
From the label in effect Oct 7, 2026.
AVOPEF is a topoisomerase inhibitor indicated, in combination with other chemotherapy and/or immunotherapy, for the treatment of adult patients with: Refractory testicular cancer ( 1.1 ) Small cell lung cancer ( 1.2 ) 1.1 Refractory Testicular Cancer AVOPEF, in combination with chemotherapy, is indicated for the treatment of refractory testicular cancer in adult patients. 1.2 Small Cell Lung Cancer AVOPEF, in combination with chemotherapy and immunotherapy, is indicated for the first-line treatment of small cell lung cancer (SCLC) in adult patients.
Mechanism: Etoposide causes the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals, leading to cell cycle arrest, primarily at the G2 stage of the cell cycle, and cell death.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- AVOPEF · ETOPOSIDE 100MG/5ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- AVOPEF · ETOPOSIDE 500MG/25ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Etoposide" as an intervention, any sponsor and status, largest first.
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT00430118 · 4,559 participants · Start Jul 2000 · Primary completion Jan 2012
Drug: asparaginase; cyclophosphamide and 12 more · For: Leukemia
Sites: Dornbirn, Austria; Feldkirch-Tisis, Austria; Graz, Austria · 76 sites in all
- Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingStatus unknown
University Hospital, MotolAcademic, hospital or other
NCT00764907 · 4,000 participants (planned) · Start Nov 2002 · Primary completion Oct 2007
Drug: asparaginase; cyclophosphamide and 13 more · For: Leukemia
Sites: Prague, Czechia
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
Societe Internationale d'Oncologie PediatriqueAcademic, hospital or other
NCT00276640 · 3,417 participants · Start Apr 1, 2004 · Primary completion Dec 31, 2015
Drug: vincristine, carboplatin; vincristine, carboplatin, etoposide · For: Primary Central Nervous System Neoplasms
Sites: Vienna, Austria; Ghent, Belgium; Zagreb, Croatia · 13 sites in all
- Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung CancerPivotal-lookingCompleted
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT00002823 · 3,300 participants (planned) · Start Feb 1995 · Primary completion Jan 2001
Drug: cisplatin; etoposide and 3 more · For: Lung Cancer
Sites: Atlantis, Florida; Boston, Massachusetts; Buenos Aires, Argentina · 123 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use8,393
- febrile neutropenia7,746
- neutropenia5,069
- drug ineffective4,759
- disease progression4,532
- thrombocytopenia4,140
- pyrexia3,405
- anaemia3,353
- sepsis2,998
- product use in unapproved indication2,973
- death2,838
- pancytopenia2,784
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 792 |
| 2005 | 881 |
| 2006 | 745 |
| 2007 | 988 |
| 2008 | 1,084 |
| 2009 | 1,045 |
| 2010 | 1,167 |
| 2011 | 1,773 |
| 2012 | 1,995 |
| 2013 | 1,567 |
| 2014 | 1,702 |
| 2015 | 2,269 |
| 2016 | 2,601 |
| 2017 | 3,664 |
| 2018 | 4,656 |
| 2019 | 4,902 |
| 2020 | 5,842 |
| 2021 | 5,788 |
| 2022 | 6,631 |
| 2023 | 6,994 |
| 2024 | 6,507 |
| 2025 | 5,644 |
| 2026 | 4,206 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, et al. · Lancet 2019 · Clinical Trial, Phase III, Multicenter Study
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, et al. · Lancet Oncol 2021 · Clinical Trial, Phase III, Comparative Study
- Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
Reck M, Dziadziuszko R, Sugawara S, et al. · Lung Cancer 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Peters C, Dalle JH, Locatelli F, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE, Krailo MD, Tarbell NJ, et al. · N Engl J Med 2003 · Clinical Trial, Multicenter Study
- Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B, Kirton L, Marec-Bérard P, et al. · Lancet 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Avyxa Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.